Arena Looks To Partnering Strategy While Hoping For Belviq Resurrection
This article was originally published in The Pink Sheet Daily
The firm's entire pipeline is up for partnering, interim CEO Hixson says, while Arena awaits CV outcomes data and approval of an extended-release version of Belviq.
You may also be interested in...
Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol
The latest drug development news and highlights from our FDA Performance Tracker
The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.